Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
SODIUM CHLORIDE
Baxter Healthcare Limited
Solution for Infusion
2002-04-05
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pentastarch 6% in 0.9% Sodium Chloride Intravenous Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1000 ml of solution contain: 3 PHARMACEUTICAL FORM Solution for infusion. A clear almost colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Volume replacement for ( i ) therapy of mild to moderate hypovolaemia and shock in connection with surgery, trauma, infections and burns and ( ii ) acute normovolaemic haemodilution. The solution is not to be used as a substitute for either blood or plasma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Pentastarch 6% is for intravenous use only. The therapeutic limit is set by the dilution effect. It should be considered that the intravasal volume effect is greater than the infused dose. Careful monitoring of infusion rate and dose prevents circulatory overload The initial 10-20ml should be infused slowly, with the patient under careful observation, in order to detect the occurrence of an anaphylactoid reaction as early as possible. The daily dose and infusion rate depend upon the patient’s hypovolaemia, age, weight and haemodynamic condition, and should be adjusted accordingly. In adults the amount usually administered is 500ml to 1000ml. The usual dosage does not usually exceed 1500ml/ day or 20ml per kg bw/day for a typical 70kg bw patient, but in common with other colloids the limiting dose will depend on circulating volume and haematocrit; in patients without cardiovascular or pulmonary risk the solution should only Poly(0-2-hydroxyethyl) starch (Average nominal MW 200,000 Da; molar substitution 0.5) 60.00 g Sodium Chloride 9.00 g Osmolarity 308.00 mOsm/L Colloid Osmotic Pressure 36.00 mmHg pH 3.50 - 6.50 Na+ 154.00 mmol/L Cl- 154.00 mmol/L _For Read the complete document